Caracterización clínica y metabólica de pacientes con diagnóstico de urolitiasis en una clínica de cuarto nivel en la ciudad de Barranquilla en el año 2019
| datacite.rights | http://purl.org/coar/access_right/c_16ec | eng |
| dc.contributor.advisor | Aroca Martínez, Gustavo | |
| dc.contributor.advisor | Castillo Parodi, Luis | |
| dc.contributor.advisor | Gonzales Torres, Henrry J. | |
| dc.contributor.author | Vicente Pérez, Rafael | |
| dc.date.accessioned | 2021-02-01T16:25:16Z | |
| dc.date.available | 2021-02-01T16:25:16Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Introducción:La urolitiasis es una enfermedad con alta frecuencia y nuestro medio no es la excepción, en Colombia se han publicado estudios previos, sin embargo, estos no comparan las características sociodemográficas y clínicas de los pacientes con las comorbilidades y factores predisponentes de litiasis como lo son hiperuricemia, hipertensión arterial, obesidad y enfermedad renal crónica (ERC). Objetivos:Caracterizar clínica y metabólicamentelos pacientes con diagnóstico de urolitiasis en una clínica de cuarto nivel de la ciudad de Barranquilla en el año 2019. Materiales y Métodos:Estudio observacional, descriptivo, transversal. Se realizó un análisis determinando medidas de tendencia central, dispersión y frecuencias asociado a un análisis bivariado. Resultados:Se incluyeron 49 pacientes. La mediana de edad fue 58 años, el sexo masculino en 53,1%. La mediana del índice de masa corporal fue de 26,4Kg/m2. Se identificó hipertensión arterial en 69,4%, enfermedad renal crónica (ERC) en 36,7%, infección de vías urinarias recurrente en 24,5%. Hiperuricemia en 44,9%, hipercalcemia en 16,3% e hiperfosfatemia en 12,2%.Los tipos de cristal fueron oxalato en 20,4%, urato en 12,2%, mezcla de los previos en 4,1% y en igual proporción fosfato. Hipercalciuria e hiperoxaluria en 38,8%, hiperuricosuria e hipocalciuria en 18,4%, mientras hiperfosfaturia o hipofosfaturia en 4,1%.La hiperuricemia se asoció a edad (p=0,028), ERC (p=0,026), medicamentos antihipertensivos (p=0,022), la posición del cálculo en cáliz renal (p= 0,012), hiperparatiroidismo (p= 0,007), depuración de creatinina (p= 0,046) e hipercalciuria (p= 0,049).IMC ≥30 se asoció con ERC estadio 5 (p=0,025), diálisis (p=0,025) y hiperoxaluria (p= 0,021). Conclusiones:Se evidencio en pacientes con urolitiasis una frecuencia significativa de ERC, hiperuricemia, obesidad e hipertensión arterial. | spa |
| dc.description.abstract | Background: Urolithiasis is a disease with high frequency and our environment is no exception. Previous studies have been published in Colombia; however, they do not evaluate Caribbean regionpopulation. Objectives: to characterize clinically and metabolically patients diagnosed with urolithiasis in the clinic of La Costa in Barranquilla in 2019. Materials and Methods: observational, descriptive, cross-sectional study. An analysis was carried out determining measures of central tendency, dispersion and frequencies associated with a bivariate analysis. Results: 49 patients were included. The median age was 58 years, the male sex in 53.1%. The median body mass index was 26.4 Kg/m2. Arterial hypertension was identified in 69.4%, chronic kidney disease (CKD) in 36.7%, recurrent urinary tract infection in 24.5%. Hyperuricemia in 44.9%, hypercalcemia in 16.3% and hyperphosphatemia in 12.2%. The crystal types were oxalate in 20.4%, urate in 12.2%, mixture of the previous ones in 4.1% and in the same proportion phosphate. Hypercalciuria and hyperoxaluria in 38.8%, hyperuricosuria and hypocalciuria in 18.4%, while hyperphosphaturia or hypophosphaturia in 4.1%. Hyperuricemia was associated with age (p=0.028), CKD (p=0.026), antihypertensive drugs (p=0.022), the position of the stone in renal calyx (p = 0.012), hyperparathyroidism (p=0.007), creatinine clearance (p = 0.046) and hypercalciuria (p = 0.049). BMI ≥30 was associated with stage 5 CKD (p = 0.025), dialysis (p = 0.025), and hyperoxaluria (p=0.021). Conclusions: A statistically significant relationship of urolithiasis and CKD, hyperuricemia, obesity and hypertension was evidenced. It is an analysis that allows a comparison to be made with other populations already described previously. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/7044 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Urolitiasis | spa |
| dc.subject | Estudio metabólico | spa |
| dc.subject | Epidemiologia | spa |
| dc.subject | Colombia | spa |
| dc.subject | Urolithiasis | eng |
| dc.subject | Metabolic study | eng |
| dc.subject | Epidemiology | eng |
| dc.subject | Colombia | eng |
| dc.title | Caracterización clínica y metabólica de pacientes con diagnóstico de urolitiasis en una clínica de cuarto nivel en la ciudad de Barranquilla en el año 2019 | spa |
| dc.title.translated | Clinical and metabolic characterization of patients with a diagnosis of urolithiasis in a four level clinic in the city of Barranquilla in 2019 | eng |
| dc.type.driver | info:eu-repo/semantics/other | eng |
| dc.type.spa | Otros | spa |
| dcterms.references | Nieto VMG, Isabel M, Yanes L. Litiasis renal . Nefrología al día. 2019. p. 133–47. | spa |
| dcterms.references | Santos FM Dos, Peres AK, Mandotti MR, Peres LAB. Metabolic investigation in patients with nephrolithiasis. Einstein (Sao Paulo). 2017;15(4):452–6. | eng |
| dcterms.references | Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, et al. Kidney stones. Nat Rev Dis Prim . 2016;2:1–23. | spa |
| dcterms.references | Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol. 2017;58(5):299–306. | eng |
| dcterms.references | Aponte V HA, Blanco R LA, Hernández S FL, Larios G. CA, Romero W. G, Salazar T. GA, et al. Guías de estudio metabólico de la litiasis. Basadas en la evidencia. Rev Urol Colomb / Colomb Urol J. 2006;XV(1):117–21. | spa |
| dcterms.references | Pfau A, Knauf F. Update on Nephrolithiasis: Core Curriculum 2016. Am J Kidney Dis . 2016;68(6):973–85. | eng |
| dcterms.references | Tang X, Lieske JC. Acute and chronic kidney injury in nephrolithiasis. Curr Opin Nephrol Hypertens. 2014;23(4):385–90. | eng |
| dcterms.references | Ordoñez J, De Reina G. Diagnóstico y manejo clínico del paciente con Urolitiasis. Acta Medica Colomb. 1978;3(2):111–24. | spa |
| dcterms.references | Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535–43. | eng |
| dcterms.references | Spivacow FR, Del Valle EE, Lores E, Rey PG. Kidney stones: Composition, frequency and relation to metabolic diagnosis. Medicina (B Aires). 2016;76(6):343–8. | eng |
| dcterms.references | Rodríguez CE. Análisis metabólico de los pacientes con litiasis renal. Papel de la hipocitraturia en la génesis de los cálculos de oxalato de calcio. Rev la Fac Med. 1996;44(2):70–4. | spa |
| dcterms.references | Gordiano EA, Tondin LM, Miranda RC de, Baptista DR, Carvalho M. Evaluation of food intake and excretion of metabolites in nephrolithiasis. J Bras Nefrol. 2014;36(4):437–45. | eng |
| dcterms.references | Cuenta de alto costo. Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia – 2018. 2018. p. 1–65. | spa |
| dcterms.references | Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Eur Urol . 2016 Mar;69(3):468–74. | eng |
| dcterms.references | Gilberto González V. Litiasis renal: estudio y manejo endocrinológico. Rev Médica Clínica Las Condes. 2013;24(5):798–803. | spa |
| dcterms.references | Fink H, Wilt T, Eidman K. Recurrent Nephrolithiasis in Adults : Comparative Effectiveness of Preventive. Agency Healthc Res Qual. 2013;(61). | eng |
| dcterms.references | Toro-Bermúdez R, Ruiz-Londoño D, Benavides-Martínez JA, Velásquez-Ossa DA, Castellanos RI, Henao-Velásquez M, et al. Prevalencia de complicaciones mayores en nefrolitotomía percutánea en una clínica de tercer nivel en Medellín entre 2015–2017. Rev Urol Colomb / Colomb Urol J. 2019; | spa |
| dcterms.references | Padilla ÁS, Andrade FO, Guerra WA, Sánchez JG, Villazón JF, Zapata M, et al. Nefrolitotomía retrógrada flexible láser de holmium: Primeros 100 casos. Urol Colomb . 2014;23(2):103–8. | spa |
| dcterms.references | Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int. 2004;72(SUPPL. 1):1–5. | eng |
| dcterms.references | Kummer AE, Grams M, Lutsey P, Chen Y, Matsushita K, Köttgen A, et al. Nephrolithiasis as a risk factor for CKD: The atherosclerosis risk in communities study. Clin J Am Soc Nephrol. 2015;10(11):2023–9. | eng |
| dcterms.references | Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: Prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004;44(5):799–805. | eng |
| dcterms.references | Cano-García M del C, Ochoa-Hortal MÁ. Value of urinary metabolic study in patients with recurrent renal stones. Study in or a Health Area. Actual Medica. 2014;99(793):136–9. | eng |
| dcterms.references | Martín Arrabal M, Rodríguez Fernández A, Arrabal Polo MÁ, Ruíz Garcia MJ, Zuluaga Gomez A. Estudio de factores físico-químicos en pacientes con litiasis renal. Arch Españoles Urol. 2006;59(6):583–94. | spa |
| dcterms.references | Hadian B, Zafar-Mohtashami A, Ghorbani F. Study of urine composition of patients with recurrent nephrolithiasis in Lorestan, Iran. Iran J Kidney Dis. 2018;12(1):22–6. | eng |
| dcterms.references | Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Effect of socioeconomic status on 24-hour urine composition in patients with nephrolithiasis. Urology . 2012;80(1):43–7. | eng |
| dcterms.references | Peres LAB, de Almeida LP, Bolson LB, Brites M de F, David JM, Tazima L. Investigation of nephrolithiasis in the West of Paraná. J Bras Nefrol . 2011;33(2):160–5. | eng |
| dcterms.references | García-Perdomo HA, Solarte PB, España PP. Fisiopatología asociada a la formación de cálculos en la vía urinaria. Urol Colomb . 2016;25(2):109–17. | spa |
| dcterms.references | Alelign T, Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018. | eng |
| dcterms.references | Shoag J, Tasian GE, Goldfarb DS, Eisner BH. The New Epidemiology of Nephrolithiasis. Adv Chronic Kidney Dis . 2015;22(4):273–8. | eng |
| dcterms.references | Landgren AJ, Jacobsson LTH, Lindström U, Sandström TZS, Drivelegka P, Björkman L, et al. Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study. Arthritis Res Ther. 2017;19(1):1–9. | eng |
| dcterms.references | Parmar MS. Kidney stones. BMJ . 2004 Jun 12;328(7453):1420–4. | eng |
| dcterms.references | Mayans L. Nephrolithiasis. Prim Care - Clin Off Pract. 2019;46(2):203–12. | eng |
| dcterms.references | Peres LAB, Ferreira JRL, Beppu APK, de Araújo Junior ER, Vicenzi G, Yamamoto RYT. [Anatomical alterations in patients with nephrolithiasis]. J Bras Nefrol. 2010;32(1):33–6. | eng |
| dcterms.references | Knoedler JJ, Krambeck AE, Astorne W, Bergstralh E, Lieske J. Sex steroid hormone levels may not explain gender differences in development of nephrolithiasis. J Endourol. 2015;29(12):1341–5. | eng |
| dcterms.references | Pigna F, Sakhaee K, Adams-Huet B, Maalouf NM. Body fat content and distribution and urinary risk factors for nephrolithiasis. Clin J Am Soc Nephrol. 2014;9(1):159–65. | eng |
| dcterms.references | Masterson JH, Woo JR, Chang DC, Chi T, L’Esperance JO, Stoller ML, et al. Dyslipidemia is associated with an increased risk of nephrolithiasis. Urolithiasis . 2015 Feb 6;43(1):49–53. | eng |
| dcterms.references | Sohgaura A, Bigoniya P. A Review on Epidemiology and Etiology of Renal Stone. Am J Drug Discov Dev. 2017;7(2):54–62. | eng |
| dcterms.references | Ortegón-Gallareta R, Aguilar-Moreno J, Pech-Cervantes PI, Álvarez-Baeza A, Méndez-Domínguez N. Epidemiologic profile of hospitalizations due to urolithiasisin the state of Yucatán, Mexico. Rev Mex Urol. 2019;79(5):1–11. | eng |
| dcterms.references | Bansal AD, Hui J, Goldfarb DS. Asymptomatic nephrolithiasis detected by ultrasound. Clin J Am Soc Nephrol. 2009;4(3):680–4. | eng |
| dcterms.references | Lin K, Dowling S. Ultrasonography versus computed tomography for initial investigation of suspected nephrolithiasis. Can J Emerg Med. 2016;18(4):315–8. | eng |
| dcterms.references | Colombo G, Solbiati M. Ultrasonography versus computed tomography for suspected nephrolithiasis. Intern Emerg Med. 2015;10(4):515–6. | eng |
| dcterms.references | Bos S, Nap RRH, Wouters RSME, van der Kleij FGH. Hypocitraturia: A common but not well-known cause of nephrolithiasis. Neth J Med. 2014;72(10):545–7. | eng |
| dcterms.references | Cicerello E, Mangano M, Cova GD, Merlo F, Maccatrozzo L. Metabolic evaluation in patients with infected nephrolithiasis: Is it necessary? Arch Ital di Urol e Androl. 2016;88(3):208–11. | eng |
| dcterms.references | Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(9):659–67. | eng |
| dcterms.references | Marchini GS, Ortiz-Alvarado O, Miyaoka R, Kriedberg C, Moeding A, Stessman M, et al. Patient-centered medical therapy for nephrolithiasis. Urology . 2013;81(3):511–6. | eng |
| dcterms.references | Lotan Y, Jiménez IB, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, et al. Primary prevention of nephrolithiasis is costeffective for a national healthcare system. BJU Int. 2012;110(11 C). | eng |
| dcterms.references | Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body Mass Index and Risk for End-Stage Renal Disease. Ann Intern Med 2006;144:21. | eng |
| dcterms.references | Sakhaee K. Unraveling the mechanisms of obesity-induced hyperoxaluria. Kidney Int 2018;93:1038–40. | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | eng |
| sb.programa | Especialización en Nefrología | spa |
| sb.sede | Sede Barranquilla | spa |